Invesco Pharmaceuticals ETF
PJP
105 hedge funds and large institutions have $69.2M invested in Invesco Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
17% more capital invested
Capital invested by funds: $59M → $69.2M (+$10.2M)
13% more funds holding
Funds holding: 93 → 105 (+12)
0.24% less ownership
Funds ownership: 22.23% → 21.99% (-0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$1.87M |
| 2 |
HAS
HBW Advisory Services
Simi Valley,
California
|
+$513K |
| 3 |
GC
Grimes & Company
Westborough,
Massachusetts
|
+$483K |
| 4 |
SWGC
Summit Wealth Group (Colorado)
Colorado Springs,
Colorado
|
+$428K |
| 5 |
BlackRock
New York
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.15M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$504K |
| 4 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
-$342K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$79.4K |
PJP Hedge Fund Activity: Q4 2025 in Review
105 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2025, worth a combined $69.2M — up 17% from $59M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PJP positions and 7 closed out — a net gain of 13 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Wells Fargo, adding an estimated $1.87M. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.15M sold.
- 105 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2025, up from 93 in Q3 2025.
- Funds reported $69.2M of Invesco Pharmaceuticals ETF stock for Q4 2025, up 17% quarter-over-quarter.
- 20 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2025 and 7 closed out, a net change of +13 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q4 2025 was Wells Fargo, an estimated $1.87M added.
- The largest Invesco Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $2.15M sold.
Based on aggregated 13F filings for Q4 2025.